An interview with Dr. George Adams, CEO of VentriPoint Diagnostics Ltd. (TSXV:VPT) (VPTDF.PK). VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. Management believes the VMS(TM) is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure, which management believes has a multibillion-dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of VentriPoint's VMS(TM) heart analysis system and VentriPoint is pursuing the US-FDA approval through the 510(k) process.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! (Read Full Disclaimer at http://crwenewswire.com/disclaimer